{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T10:57:33Z","timestamp":1787828253652,"version":"build-2784847793"},"reference-count":48,"publisher":"Informa UK Limited","issue":"17","license":[{"start":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T00:00:00Z","timestamp":1646956800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.2217\/fon-2021-1486","type":"journal-article","created":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T08:38:37Z","timestamp":1646987917000},"page":"2041-2051","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":16,"title":["STARBOARD: encorafenib + binimetinib + pembrolizumab for first-line metastatic\/unresectable\n            <i>BRAF<\/i>\n            V600-mutant melanoma"],"prefix":"10.1080","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3524-7858","authenticated-orcid":false,"given":"Dirk","family":"Schadendorf","sequence":"first","affiliation":[{"name":"Department of Dermatology,University Hospital Essen, 45122 Essen,Germany &amp; German Cancer Consortium,Partner Site Essen,\rGermany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2279-6906","authenticated-orcid":false,"given":"Reinhard","family":"Dummer","sequence":"additional","affiliation":[{"name":"Department of Dermatology,University Hospital Z\u00fcrich &amp; University Zurich,\rZurich,\r8091,\rSwitzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9493-0238","authenticated-orcid":false,"given":"Caroline","family":"Robert","sequence":"additional","affiliation":[{"name":"Melanoma Research Unit,Institut Gustave Roussy,\rVillejuif,\r94805,\rFrance"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3669-8458","authenticated-orcid":false,"given":"Antoni","family":"Ribas","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology-Oncology,University of California,\rLos Angeles, Los Angeles,\rCA 90095,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5344-6645","authenticated-orcid":false,"given":"Ryan J","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital,Harvard Medical School,\rBoston,\rMA 02115USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Panella","sequence":"additional","affiliation":[{"name":"Department of Medicine,Division of Hematology &amp; Oncology,University of Tennessee,\rKnoxville,\rTN 37996,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0944-7418","authenticated-orcid":false,"given":"Meredith","family":"McKean","sequence":"additional","affiliation":[{"name":"Sarah Cannon Research Institute at Tennessee Oncology,\rNashville,\rTN 37203,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgardo S","family":"Santos","sequence":"additional","affiliation":[{"name":"Florida Precision Oncology\/A Division of Genesis Care USA,Florida Atlantic University,\rAventura,\rFL 33180,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberli","family":"Brill","sequence":"additional","affiliation":[{"name":"Pfizer,La Jolla,\rCA 92037,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Polli","sequence":"additional","affiliation":[{"name":"Pfizer S.R.L.,Milan,\r20152,\rItaly"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra di","family":"Pietro","sequence":"additional","affiliation":[{"name":"Pfizer,La Jolla,\rCA 92037,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8322-475X","authenticated-orcid":false,"given":"Paolo A","family":"Ascierto","sequence":"additional","affiliation":[{"name":"Istituto Nazionale Tumori IRCCS Fondazione Pascale,\rNapoli,\r80131,\rItaly"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,3,11]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature00766"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.4327"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210421"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-020-00509-z"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31601-X"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910836"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503093"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709684"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.2850"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar4060"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz011"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002011"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103782"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60868-X"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112302"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70012-9"},{"key":"e_1_3_4_20_1","article-title":"National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology","author":"National Comprehensive Cancer Network","year":"2021","unstructured":"National Comprehensive Cancer Network . National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Melanoma: Cutaneous. Version 2.2021. (2021). www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1492","journal-title":"Melanoma: Cutaneous. Version 2.2021."},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz411"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412690"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60898-4"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30388-2"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30122-X"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.11.016"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.9507"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.11.019"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.12.012"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4618-9"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-1630"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-0118"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-1626"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.4161\/onci.22890"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.01.024"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-2479"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.4161\/onci.26615"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2023"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-021-01872-3"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/9235638"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1904059"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1082-2"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30934-X"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001806"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.08.2273"},{"issue":"5","key":"e_1_3_4_46_1","first-page":"1091TiP","article-title":"STARBOARD: randomized phase III study of encorafenib (enco) + binimetinib (bini) + pembrolizumab (pembro) for first-line treatment of metastatic or unresectable locally advanced BRAF V600-mutant melanoma","volume":"32","author":"Schadendorf D","year":"2021","unstructured":"Schadendorf D , DummerR, RobertCet al. STARBOARD: randomized phase III study of encorafenib (enco) + binimetinib (bini) + pembrolizumab (pembro) for first-line treatment of metastatic or unresectable locally advanced BRAF V600-mutant melanoma. Ann. Oncol.32(Suppl. 5), 1091TiP (2021).","journal-title":"Ann. Oncol."},{"key":"e_1_3_4_47_1","unstructured":"BRAFTOVI \u00ae (encorafenib) prescribing information (2020). www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/210496s006lbl.pdf"},{"key":"e_1_3_4_48_1","unstructured":"MEKTOVI \u00ae (binimetinib) prescribing information (2019). www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/210498s001lbl.pdf"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.9532"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01464"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2021-1486","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:46:03Z","timestamp":1719125163000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2021-1486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,11]]},"references-count":48,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10.2217\/fon-2021-1486"],"URL":"https:\/\/doi.org\/10.2217\/fon-2021-1486","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,11]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-11-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}